Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) Debt to Equity (2016 - 2026)

Usana Health Sciences has reported Debt to Equity over the past 7 years, most recently at $0.03 for Q2 2026.

  • Quarterly Debt to Equity fell 40.67% to $0.03 in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $0.03 through Apr 2026, down 40.67% year-over-year, with the annual reading at $0.03 for FY2026, 39.24% down from the prior year.
  • Debt to Equity was $0.03 for Q2 2026 at Usana Health Sciences, down from $0.03 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.04 in Q1 2025 and troughed at $0.0 in Q4 2023.
  • The 5-year median for Debt to Equity is $0.03 (2026), against an average of $0.02.
  • Year-over-year, Debt to Equity soared 2634.25% in 2024 and then crashed 40.67% in 2026.
  • A 5-year view of Debt to Equity shows it stood at $0.03 in 2022, then plummeted by 93.84% to $0.0 in 2023, then soared by 2634.25% to $0.04 in 2024, then grew by 0.44% to $0.04 in 2025, then plummeted by 40.67% to $0.03 in 2026.
  • Per Business Quant, the three most recent readings for USNA's Debt to Equity are $0.03 (Q2 2026), $0.03 (Q1 2026), and $0.04 (Q1 2025).